Although there are complicated regulatory mechanisms on p62, we suggest that YAP‐ERK signaling can control the expression of p62 in lung cancer and our clinical data support the clinical relevance of interaction between YAP and p62 in lung adenocarcinoma. Here, SQSTM1 is linked to lung cancer.